Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04666259 · ClinicalTrials.gov registry record · Phase 3
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
NCT04666259 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT04666259, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study was a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior TKI
Interventions
- DRUG ABL001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04666259
The ClinicalTrials.gov registry entry for NCT04666259 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABL001 is the first listed.
NCT04666259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04666259 about?
NCT04666259 is a clinical study titled "Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation". This study was a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior TKI
What is the current status of trial NCT04666259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2021-05-25. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT04666259?
The interventions under investigation include: ABL001 (DRUG).
Who is sponsoring clinical trial NCT04666259?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.